Advanced or Metastatic renal cell carcinoma (RCC)

Predominant clear cell histology:

1. At least 1 but no more than 2 prior systemic anti vascular endothelial growth factor (anti-VEGF) treatments

2. No more than 3 total prior systemic treatment regimens in the advanced or metastatic setting

3. Subjects with prior treatment with a mechanistic target of rapamycin (mTOR) are eligible

Non-clear cell histology: 0-3 prior systemic therapies and may include mTOR inhibitor

Brain metastases allowed if asymptomatic, without edema, and not receiving corticosteroids or radiation

Performance Status (PS): ≥ 70% Karnofsky Performance Scale (KPS)

All Memorial Sloan-Kettering Cancer Center (MSKCC) prognostic scores allowed

An Investigational Immuno-therapy Safety Trial of Nivolumab in Patients With Advanced or Metastatic Renal Cell Carcinoma